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Efforts continue to reduce the timeline and cost of progressing biologics from discovery through preclinical 
development to product launch.  Integrated processes, those that link upstream and downstream processing 
with control of product quality are an attractive way to achieve meaningful reductions in the overall cost of 
ownership of a biologics manufacturing process.   
 
To start along this path, an integrated continuous processing laboratory, the PROLab (Protein Refinery 
Operations Lab) was built to pilot the concepts of an integrated continuous antibody manufacturing process 
under automated control.  A perfusion process was developed capable of operating for >30 days using either 
TFF (Spectrum KrosFlo® perfusion system) or alternating tangential flow (Repligen ATF system).  The biomass 
in the perfusion process was controlled at constant density (~50 million cells per ml) via automated feedback 
loop using an online capacitance probe.  The product containing permeate was depth filtered and continually fed 
into the purification unit operations; consisting of protein A via simulated moving bed, viral inactivation, a 
polishing step, viral filtration, and a concentration step.  A PATROL UPLC system from Waters equipped with an 
online QDA mass spec was used to continually monitor, with the ultimate goal of controlling, product quality 
attributes at multiple points across the upstream and downstream process.  In addition, the PATROL system 
was used to monitor key metabolites in the upstream process.  Uniquely, both the upstream and downstream 
processes were coordinated and controlled using a DeltaV based automation system.  The automation 
coordinated inter-stage adjustments and checks, as well as managing the speed of material flow through the 
purification process ensuring optimal operation.  In summary, the PROLab environment will enable the evolution 
of the antibody manufacturing platform towards fully integrated and continuous by providing a proving ground for 
both processes and technologies; thereby building high quality and robust automated and continuous 
manufacturing platforms. 
